PCa Commentary

PCa Commentary

PCa Commentary: Expert Commentary On The Latest Prostate Cancer Topics

The Prostate Cancer Treatment Research Foundation is proud to host Dr. Edward Weber’s PCa Commentary. PCa Commentary is a well-researched, clearly presented commentary targeted to medical providers and others interested in current prostate cancer treatment. Each PCa Commentary edition offers an analysis of new developments in the field of prostate cancer with essays discussing and evaluating treatment management options for this disease.

About the Author: Edward Weber, M.D.

Edward Weber, M.D. is a retired medical oncologist living in Seattle. Washington. He was born and raised in a suburb of Reading, Pennsylvania. After graduating from Princeton University in 1956 with a BA in History, he attended medical school at the University of Pennsylvania. His internship training took place at the University of Vermont in Burlington, Vermont.

A tour of service as a Naval Flight Surgeon positioned him on Whidbey Island, Washington, and this introduction to the Pacific Northwest ultimately proved irresistible. Following naval service, he received postgraduate training in internal medicine in Philadelphia at the Pennsylvania Hospital and then he pursued a fellowship in hematology and oncology at the University of Washington.

His career in medical oncology was at the Tumor Institute of the Swedish Hospital in Seattle where his practice focused largely on the treatment of patients experiencing lung, breast, colon, and genitourinary cancer and malignant lymphoma.

Toward the end of his career he developed a particular concentration on the treatment of prostate cancer. Since retirement in 2002 he has authored the PCa Commentary, published by the Prostate Cancer Treatment Research Foundation, an analysis of new developments in the prostate cancer field with essays discussing and evaluating treatment management options in this disease. He is a regular speaker at various prostate cancer support groups around Seattle.

Contact the Author: Edward Weber, M.D.

Your comments, requests for information on a specific or new PCa Commentary are welcome. Feel free to email Dr. Weber directly using this link: email Dr. Weber


PCa Commentary -Recent Editions


January, 2017

Vol. 108 Androgen Deprivation Therapy Adjuvant to Radiotherapy: New Mechanistic Insights with Clinical Implications.

December, 2016

Vol. 107 Adverse Effects: Doctor, What are the Side Effects of your Treatment.

November, 2016

Vol. 106 Compare Treatment Outcomes – Surgery VS Radiotherapy: Is it Even Possible…or Necessary?

October, 2016

Vol. 105 Follicle Stimulating Hormone (FSH): It’s Suppression by Degarelix (Firmagon) may contribute to the drug effectiveness in androgen suppression and its lesser cardiotoxicity compared to Leuprolide (Lupron.)

September, 2016

Vol. 104 A Rising PSA!…When to start Androgen Suppression…no clear guidelines.

August, 2016

Vol. 103  The (18)F-fluciclovine Total-Body PET?CT Scan (Trade named “Axumin,” aka FACBC) is Now Approved for Recurrent Prostate Cancer; It’s availability is likely to impact clinical management decisions.

July, 2016

Vol. 102  An MRI Protocol for “One-Stop-Shopping” for Staging in Newly Diagnosed Prostate Cancers.

June, 2016

Vol. 101  Androgen Deprivation Therapy: A Cautionary Note for Cardiac Patients.

May, 2016

Vol. 100 Decipher: A Useful Tool in Post-Prostatectomy Treatment Planning?

April, 2016

Vol. 99  OLAPARIB- A Promising New Agent for Treatment of Prostate Cancer for a Subset of Men Carrying Specific Gene Mutations.

March, 2016

Vol. 98 PSA Testing for Aggressive Prostate Cancer

January- February, 2016
Vol. 97.1 Radiation Therapy: The ASCENDE Trial
Vol. 97.2 Bipolar Androgen Therapy (BAT)
Vol. 97.3 Cyberknife SBRT

November-December, 2015
Vol. 96.1 Chemotherapy AND Androgen Suppression
Vol. 96.2 Metformin

July-August, 2015
Vol. 94.1 Bone Scanning: Which Scan and Why
Vol. 94.2 Enzalutamide (Xtandi) A Brief Synopsis- Present Status; Current Research

May – June, 2015
Vol. 93.1 ACTIVE SURVEILLANCE: Outcomes and Lessons From Long-Term Follow-up
Vol. 93.2 ACTIVE SURVEILLANCE UTILIZATION
Vol. 93.3 PROSTVAC – A Promising Prostate Cancer Vaccine Under Development: A Primer

March – April, 2015
Vol. 92.1: GENOMIC PROFILERS for RISK STRATIFICATION: A Primer: What Are They? How Can They Help in Clinical Management?
Vol. 92.2: OLIGOMETASTATIC PROSTATE CANCER: What Is It? A Potential Option for Limited Therapy?
Vol. 92.3: THE FUTURE OF WHOLE-BODY IMAGING: The 18F-FACBC PET/CT — Currently Under Development

January – February, 2015
Vol. 91.1: ACTIVE SURVEILLANCE AND MULTIPARAMETRIC MRI: A PROMISING COMBINATION FOR A NEW PARADIGM — mpMRI Targeted Biopsy for Patient Selection; mpMRI for Sequential Monitoring. A Vision of the Future.
Vol. 91.2: YOUR PSA IS “UNDETECTABLE”: What Does That Mean? How Does An “Undetectable” PSA Affect Management?

November – December, 2014
Vol. 90.1: Androgen Deprivation Therapy…But Without Lowering Serum Testosterone? An oxymoron?
Vol. 90.2: ANDROGEN RECEPTOR SPLICE VARIANT-V7: A Head’s Up — Its presence renders both Zytiga and Xtandi ineffective.
Vol. 90.3: Initiating Androgen Deprivation Therapy in Patients with PSA-only Relapse: When to Start?

September – October, 2014
Vol. 89: ADT: Less may be more


PCA Commentary Archives


Vol. 88: July – August, 2014

  • THE VENERABLE PSA TEST: Sharpening Its Diagnostic Focus
  • SEQUENCING THE NEW AGENTS IN THE TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER: Clinicians now have an abundance of riches but await guidelines for their best use.

Vol. 87: May – June, 2014

  • ACTIVE SURVEILLANCE: Still a Work in Progress – Current Focus: Refining Patient Selection
  • FIRMAGON AND LUPRON — Both Lower Testosterone; They Are Not Identical Drugs

Vol. 86: March – April, 2014

  • Special Issue on Xtandi – Xtandi ( aka enzalutamide ): Just The Facts, Please

Vol. 85: January – February, 2014

  • HIGH-RISK PROSTATE CANCER: Can the Definition Be Improved To More Accurately Predict Risk of PSA Recurrence and Prostate Cancer-Specific Mortality?
  • TESTOSTERONE RECOVERY After Six Months of Androgen Suppression: What can be learned from recent studies?

Vol. 84: November – December, 2013

  • INTERMEDIATE-RISK PROSTATE CANCER: Dose-Escalated Radiotherapy; New Understanding of Androgen Deprivation and Who Benefits From IT?
  • BRACHYTHERAPY: Optimal Prostate Dose May Obviate the Need for Adjuvant Androgen Deprivation Therapy

Vol. 83: September – October, 2013

  • ALPHARADIN (Radium-233); trade name, Xofigo Is now FDA approved for use in men with castrate-resistant prostate cancer with out symptomatic bone metastases
  • PTEN A currently “hot” gene that carries prognostic significance in prostate cancer

Vol. 82: July – August, 2013

  • ZYTIGA (Abiraterone): Just the Facts, Please
  • Xtandi (enzalutamide): Moving Up Front – A Game Changer
  • Provenge: Benefit Increases When Used at Lower Baseline PSA Values

Vol. 81: May – June, 2013

  • MORE ABOUT DEGARELIX: New Findings About Its Biological Effects and Two Recent Studies
  • PROTON BEAM THERAPY FOR PROSTATE CANCER: The New “Emperor?”
  • ANDROGEN DEPRIVATION THERAPY AND DIABETES: Awareness of the association is essential for comprehensive clinical management
  • METFORMIN, PROSTATE CANCER, AND DIABETES — What’s the Connection?

Vol. 80: March – April, 2013

  • ADVANCES IN MRI IMAGING TECHNOLOGY: New Technique of Fusing Multiparametric MRI Upon TRUS Data has the Potential To Upgrade the Diagnosis Of Prostate Cancer and Its Management
  • MPMRI/ULTRASOUND FUSION COMPARED TO 12-CORE SYSTEMATIC TRUS PROSTATE BIOPSY: The Advantage for Targeted Biopsies
  • USING MPMRI TO REFINE SELECTION OF OPTIMAL CANDIDATES FOR MANAGEMENT BY ACTIVE SURVEILLANCE

Vol. 79: January – February, 2013

  • Special Issue on Intermittent Androgen Deprivation
  • INTERMITTENT VERSUS CONTINUOUS ANDROGEN DEPRIVATION: TREATMENT FOR MEN WITH RISING PSA’S FOLLOWING PRIMARY TREATMENT OF LOCALIZED PROSTATE CANCER
  • FINASTERIDE and DUTASTERIDE:Inclusion in Intermittent Androgen Deprivation Prolongs “Off-Time” and Delays Biochemical and Tumor Progression
  • INTERMITTENT ANDROGEN DEPRIVATION FOR METASTATIC PROSTATE CANCER

Vol. 78: November – December, 2012

  • CLINICAL UPDATE: ALPHARADIN
  • DEGARELIX: WHAT’S OLD; WHAT’S NEW
  • MDV3100 (trade name, Xtandi; generic name, enzalutamide) – NOW FDA APPROVED
  • MRI – An Emerging Role for Selecting Candidates for Active Surveillance
  • ASPIRIN: Its Benefits Confirmed

Vol. 76: July – August, 2012

  • PROTON BEAM, A BETTER THERAPY FOR PROSTATE CANCER? – Where’s the Beef?
  • POMEGRANATE EXTRACT FOR PROSTATE CANCER? – Surely You Will be Asked

Vol. 75: May – June, 2012

    • A special issue on “Magnetic Resonance Imaging in Prostate Cancer”
    • MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING
    • DYNAMIC CONTRAST-ENHANCED MR IMAGING
    • IMAGING PROSTATE CANCER METASTATIC TO BONE

FERUMOXTRAN-10: An Unapproved Contrast Agent for MR Lymphography – Promising Clinical Potential; Unexpected Biology


Vol. 74: March – April, 2012

  • AN ALTERNATIVE TO LUPRON – “The Road Not Taken”
  • MDV3100 – Phase III “AFFIRM” Trial Demonstrates Survival Benefit
  • ABIRATERONE: A Brief Update
  • “ALPHARADIN” (RADIUM-223 CHLORIDE): A NEW TREATMENT FOR BONE METASTASES – Fast Tracked for FDA Approval
  • DENOSUMAB: An effective agent to prevent progression of bone metastases

Vol. 73: January – February, 2012

  • PSA AND TREATMENT DECISIONS: “What If I Don’t Treat My PSA-Detected Prostate Cancer? Answers From Three Natural History Models”…
  • ACTIVE SURVEILLANCE: “Surgical management after active surveillance for low-risk prostate cancer: pathological outcome compared with men undergoing immediate treatment.”ADJUVANT ANDROGEN DEPRIVATION WITH RADIOTHERAPY FOR INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER

* The PCa commentary is a review of current medical literature and includes the personal opinions of Doctors Weber and Grimm and does not necessarily represent the opinion of the PCRSG. These reviews should be used to assist your discussion with your physician.